-+ 0.00%
-+ 0.00%
-+ 0.00%

JAYPIRCA® (PIRTOBRUTINIB) APPROVED IN CHINA FOR A NEW INDICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) /SMALL LYMPHOCYTIC LYMPHOMA (SLL) ACROSS ALL LINES OF THERAPY

路透·09/28/2026 10:30:00

請登錄查看新聞詳情